share_log

The Recent CN¥800m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773)

Simply Wall St ·  May 21 22:41

Key Insights

  • Chengdu Kanghong Pharmaceutical Group's significant insider ownership suggests inherent interests in company's expansion
  • 54% of the business is held by the top 2 shareholders
  • Using data from company's past performance alongside ownership research, one can better assess the future performance of a company

A look at the shareholders of Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) can tell us which group is most powerful. We can see that individual insiders own the lion's share in the company with 35% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

As market cap fell to CN¥21b last week, insiders would have faced the highest losses than any other shareholder groups of the company.

Let's take a closer look to see what the different types of shareholders can tell us about Chengdu Kanghong Pharmaceutical Group.

ownership-breakdown
SZSE:002773 Ownership Breakdown May 22nd 2024

What Does The Institutional Ownership Tell Us About Chengdu Kanghong Pharmaceutical Group?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Chengdu Kanghong Pharmaceutical Group does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Chengdu Kanghong Pharmaceutical Group's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
SZSE:002773 Earnings and Revenue Growth May 22nd 2024

We note that hedge funds don't have a meaningful investment in Chengdu Kanghong Pharmaceutical Group. The company's largest shareholder is Chengdu Kanghong Technology (Group) Co., Ltd., with ownership of 32%. For context, the second largest shareholder holds about 23% of the shares outstanding, followed by an ownership of 8.7% by the third-largest shareholder. Xiao Ke, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Chengdu Kanghong Pharmaceutical Group

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

It seems insiders own a significant proportion of Chengdu Kanghong Pharmaceutical Group Co., Ltd. Insiders own CN¥7.4b worth of shares in the CN¥21b company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.

General Public Ownership

With a 26% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Chengdu Kanghong Pharmaceutical Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Company Ownership

Our data indicates that Private Companies hold 32%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Chengdu Kanghong Pharmaceutical Group has 1 warning sign we think you should be aware of.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment